Embargo: Friday July 17, 2009 at 7:40 am (Brussels time)

UNIMED PHARMACEUTICALS, LLC, DECIDES NOT TO FILE A PATENT INFRINGEMENT SUIT AT THIS TIME AGAINST PERRIGO ISRAEL PHARMACEUTICALS, LTD. FOLLOWING THE RECEIPT OF A PARAGRAPH IV CERTIFICATION FOR A GENERIC FORMULATION OF ANDROGEL® 1%

The low volume formulation of AndroGel, for which an NDA was submitted to FDA in the first quarter of 2009, is not within the scope of Perrigo's ANDA.

After careful evaluation of the Paragraph IV certifications related to the submission by Perrigo Israel Pharmaceuticals, Ltd. of an Abbreviated New Drug Application (ANDA) for a generic version of AndroGel 1%, Unimed Pharmaceuticals, LLC, a wholly-owned subsidiary of Solvay Pharmaceuticals, Inc., has decided not to file a patent infringement suit against Perrigo at this time.

As disclosed in a Solvay press release on June 10, Unimed received a letter from Perrigo advising Unimed that Perrigo had filed an ANDA with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell a generic version of AndroGel (testosterone gel) 1% CIII in the U.S. prior to the expiration of Unimed's patent. The receipt of these letters triggered a 45-day period under the Hatch-Waxman Act during which time the company could have initiated patent infringement litigation and triggered a 30-month stay of FDA approval of Perrigo's ANDA.

In its letter to the company, Perrigo asserted that it did not infringe the AndroGel patent because its proposed testosterone gel product contains a different formulation than the formulation protected by the AndroGel patent. In contrast, the proposed testosterone gel products that were the subject of earlier ANDAs filed by other companies, and which were the subject of prior patent litigation brought by the company, purported to be identical to the AndroGel formulation. This distinction played a role in the company's decision not to file patent infringement litigation at this time. However, the company does not waive its right to initiate patent infringement litigation at a later stage based on new or additional facts and circumstances.

Under the Federal Food, Drug and Cosmetic Act ("FDCA") and current FDA regulations, it is critical that any FDA-approved generic drug meet rigorous manufacturing and safety standards, including standards designed to assure

- changes in ingredients from those used by the reference listed drug do not adversely affect the proposed generic drug product's safety or effectiveness
- and that bioequivalence has been appropriately demonstrated.

Furthermore, as announced earlier, Solvay Pharmaceuticals submitted an NDA to the FDA in the first quarter of 2009 for a low volume formulation of AndroGel. This formulation is not within the scope of Perrigo's ANDA.

Solvay Pharmaceuticals remains committed to its men's health franchise and will carefully evaluate further regulatory and legal strategies to ensure patient safety and protect the interests of the company, including defending its intellectual property.

The company's long-term commitment to men suffering from low testosterone is demonstrated through

- the continued support of AndroGel patients with education and information resources and patient assistance programs
- the above mentioned NDA submission of a low volume formulation of AndroGel
- the license agreement announced in May 2009 with Lipocine, Inc. to develop an oral formulation of testosterone replacement therapy.

Unimed Pharmaceuticals, **LLC**, is a wholly-owned subsidiary of Solvay Pharmaceuticals, Inc.

Solvay Pharmaceuticals, **Inc**. of Marietta, Georgia, is the U.S. subsidiary of Solvay Pharmaceuticals. For more information, visit www.solvaypharmaceuticals-us.com.

Solvay Pharmaceuticals is a research driven group of companies that constitutes the global pharmaceutical business of the Solvay Group. These companies seek to fulfil carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology and men's and women's health. Its 2008 sales were EUR 2.7 billion, and it employs more than 9,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.

SOLVAY is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs more than 29,000 people in 50 countries. In 2008, its consolidated sales amounted to EUR 9.5 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay is listed on the NYSE Euronext stock exchange in Brussels (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR). Details are available at www.solvay.com.

For further information please contact:

ERIK DE LEYE
Corporate Press Officer
SOLVAY S.A.
Tél. : 32 2 509 7230
erik.deleye@solvay.com
www.solvaypress.com

Dr WERNER VAN DEN EYNDE
Pharmaceutical Communications
SOLVAY PHARMACEUTICALS S.A.
Tél. : 32 2 509 6227
werner.vandeneynde@solvay.com
www.solvaypharmaceuticals.com

PATRICK VERELST
Head of Investor Relations
SOLVAY S.A.
Tél. : 32 2 509 7243
patrick.verelst@solvay.com
www.solvay-investors.com

Ce communiqué de presse est également disponible en français – Dit persbericht is ook in het Nederlands beschikbaar